As blood clot concerns mounted, J&J reached out to rival COVID-19 vaccine makers to form alliance: WSJ Pfizer chief Bourla raises 'likely' need for annual COVID shots, teeing up vaccine sales for years to come EMA starts review of GSK and Vir's COVID-19 antibody therapy CureVac preps its COVID-19 shot for deployment as J&J, AZ holdups slow Europe's rollout The dogtor is in: Study finds dogs can sniff out COVID-19 with 96% accuracy COVID-19 tracker: Biden earmarks nearly $2 billion to track variants; Moderna cuts vaccine deliveries Apple launches new smartwatch study to detect COVID-19 early, especially in at-risk groups With less demand for surgical relief during pandemic, Sun cuts poppy production in Tasmania FDA walks back ‘error and ambiguity’-filled HHS proposal to exempt 91 devices from premarket review NIH funds COVID-19 testing plan to get children back in school Physician salaries held steady in 2020. Here's the one specialty that got a big pay bump during COVID-19 FCC will begin accepting applications for its $250M COVID-19 telehealth program starting April 29 Featured Story | By Noah Higgins-Dunn As concerns over cases of rare but severe blood clots among vaccinated people mounted last week, Johnson & Johnson reportedly reached out to rival COVID-19 vaccine makers for help, and only one agreed, The Wall Street Journal reports. read more |
| |
|---|
|
Top Stories By Fraiser Kansteiner Pfizer was first to market in the U.S. with its BioNTech-partnered COVID-19 vaccine, and by and large, it's avoided the safety and supply concerns plaguing some of its pandemic peers. Now, to hear CEO Albert Bourla tell it, it's increasingly likely the 2021 revenue boon will continue for years to come. read more By Nick Paul Taylor The European Medicines Agency (EMA) has begun reviewing GlaxoSmithKline and Vir Biotechnology’s anti-SARS-CoV-2 antibody. The EMA is assessing the candidate in COVID-19 patients who do not require oxygen supplementation and are at high risk of disease progression. read more By Noah Higgins-Dunn The European Union is looking to shake up its COVID-19 vaccination game plan following a turbulent start to the rollout, presenting an opportune moment for mRNA vaccine developer CureVac to enter the scene. Eying a potential market debut in the coming months, the biotech has already started vaccine production. read more By Andrea Park A new study led by researchers from the University of Pennsylvania found that mass COVID-19 screening could be solved by a quick sniff from a dog—a dognostic test, if you will. read more By Noah Higgins-Dunn,Fraiser Kansteiner,Eric Sagonowsky The Biden administration plans to spend nearly $2 billion to track emerging variants of the coronavirus. Moderna says it will slash vaccine deliveries to "a number of countries" because of European supply chain problems. And more headlines. read more By Andrea Park The Apple Respiratory Study will rely on the wearable’s optical heart sensor and self-reported weekly surveys to uncover patterns among participants who end up catching COVID, the flu and other viral infections. read more By Kevin Dunleavy Sun Pharma has cut its production of poppies in Tasmania, a result of plummeting demand for surgical pain relief during the COVID-19 pandemic. Its opioid factories are cutting back, and farmers are losing their contracts. read more By Andrea Park Normally, the FDA focuses its approval power on new drugs and devices, but in a very meta twist, the agency has issued a stern disapproval of a proposal issued in its own name earlier this year. read more By Conor Hale Over the past year, the National Institutes of Health has led “Shark Tank”-style competitions and funded radical approaches to help develop COVID-19 testing into a more seamless, ubiquitous part of daily life. Now, the NIH is looking to steer those efforts, plus new government money, toward making it safer to return to classrooms, starting in school districts with the most vulnerable children. read more By Heather Landi Despite the challenges in 2020, physicians' salaries have rebounded, along with hours working and with only a slight dip in patient volume, according to Medscape's 2021 physician compensation report. Check out the one physician specialty that saw a salary spike in 2020. read more By Dave Muoio Healthcare providers will have one week to submit applications to the second round of the program, which the FCC said will be more transparent and better prioritize rural and at-need organizations. read more |
